By Omar Sacirbey, John Schroyer and Kristen Nichols
A New Jersey court tells the state to review how it classifies marijuana, Cleveland imposes strict limits on where MMJ companies can locate, and the FDA issues warnings to CBD producers.
Here’s a closer look at some notable developments in the marijuana industry over the past week.
Cannabis schedule review
New Jersey – which is home to five medical cannabis dispensaries – made news when a state appeals court ruled that the Division of Consumer Affairs must review marijuana’s classification as a Schedule 1 substance.
Bigger news than